colorectal

Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023

TOKYO, Jan 18, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today the presentation of research across various types of gastrointestinal cancers during the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI23), which is taking place in-person in San Francisco, California and virtually from January 19-21. Notable data include... » read more

Gelonghui Reports CMS’ Successful Phase III Study of Methylthioninium Chloride Enteric-coated Sustained-release Tablets

SHENZHEN, CHINA, Dec 19, 2022 – (ACN Newswire via SEAPRWire.com) – Gelonghui released a Press Release on “China Medical System Holdings Limited’s innovative product Methylthioninium Chloride Enteric-coated Sustained-release Tablets (‘the Product’) has obtained positive results for its Phase III clinical trial in China.” This is another breakthrough for the Product after China Medical System Holdings... » read more

NEC’s artificial intelligence (AI) supports doctors to determine if colorectal lesions are potentially neoplastic

TOKYO, Jul 14, 2021 – (JCN Newswire via SEAPRWire.com) – NEC Corporation (NEC; TSE: 6701) announced today the development of an AI technology for supporting doctors in determining if colorectal lesions are neoplastic or non-neoplastic. NEC developed a new technology, called “Cx20,” while seeking to assist in the early detection of colorectal lesions. Cx20 has... » read more

Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium

TOKYO, Jan 12, 2021 – (JCN Newswire) – Eisai Co., Ltd. has announced that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, “lenvatinib”) will be given at the Gastrointestinal Cancers Symposium Virtual Meeting, from January 15 to 17, 2021. At this... » read more